Sleep apnea is among the most common chronic health conditions in the developed world, yet it remains one of the most underdiagnosed. The gap between how many people have it and how many know they have it is larger than for almost any other condition of comparable health significance. Understanding the scope of the problem — through the numbers that define its prevalence, health impact, economic cost, and diagnostic shortfall — puts individual diagnoses in a broader context and helps explain why sleep medicine has increasingly become a priority area in public health.
Prevalence — How Common Sleep Apnea Actually Is
Estimates of sleep apnea prevalence vary depending on the diagnostic criteria used, the population studied, and whether the estimate refers to any sleep-disordered breathing or only to clinically significant disease. The most widely cited figures come from large population-based studies using polysomnography in community samples.
Using an AHI threshold of 5 or more events per hour — the standard cutoff for any sleep apnea — prevalence estimates in adult populations in the United States and other developed countries range from 15% to 30% of adults, with higher rates in older age groups and men. Using a more stringent threshold of 15 or more events per hour — moderate to severe sleep apnea — estimates typically fall between 6% and 17% of adults.
A widely referenced analysis estimated that approximately 30 million adults in the United States have obstructive sleep apnea, making it more prevalent than type 2 diabetes and asthma. Globally, estimates from large epidemiological studies suggest that over 900 million adults have obstructive sleep apnea at the mild or greater severity level — a figure that places it among the most prevalent chronic conditions in the world.
The Diagnosis Gap
Perhaps the most striking of all sleep apnea facts and statistics is the scale of underdiagnosis. Despite affecting tens of millions of adults, the vast majority of sleep apnea cases remain undiagnosed. Estimates consistently place the proportion of sleep apnea patients who have received a formal diagnosis at somewhere between 10% and 20% of those affected — meaning that 80% to 90% of people with clinically significant sleep apnea do not know they have it.
Several factors contribute to this gap. Symptoms such as fatigue, poor concentration, and mood disturbance are nonspecific and attributed to other causes. Snoring is normalized by patients and partners. Primary care screening for sleep apnea is inconsistent. And until relatively recently, diagnosis required an overnight stay in a sleep lab — a barrier that home sleep testing has significantly reduced but not eliminated.
The diagnostic gap has direct health implications. Undiagnosed sleep apnea continues to exert its cardiovascular, metabolic, and cognitive effects without intervention, and patients who do not know they have the condition cannot make informed decisions about treatment.
Cardiovascular and Mortality Impact
The health consequences of untreated sleep apnea extend well beyond daytime sleepiness. The epidemiological evidence linking sleep apnea to serious cardiovascular outcomes is substantial and consistent across multiple large studies.
Hypertension is present in approximately 50% of sleep apnea patients, and sleep apnea is estimated to be the most common secondary cause of hypertension — meaning it is a direct driver of elevated blood pressure rather than a coincidental finding. Patients with severe untreated sleep apnea have a two to three times higher risk of cardiovascular death compared to matched controls without the condition, according to several long-term follow-up studies.
The stroke risk associated with sleep apnea is independently elevated — separate from the contribution of hypertension — with moderate to severe apnea roughly doubling stroke risk in some analyses. Atrial fibrillation, one of the most common cardiac arrhythmias and a major risk factor for stroke, is significantly more prevalent in sleep apnea patients, and recurrence rates after treatment of atrial fibrillation are higher in patients with untreated sleep apnea.
Economic Cost
The economic burden of sleep apnea — both direct and indirect — is substantial. Direct costs include diagnostic testing, treatment equipment, ongoing supplies, and the management of cardiovascular, metabolic, and other comorbidities that untreated sleep apnea worsens. Indirect costs include lost productivity, workplace accidents, motor vehicle accidents, and increased healthcare utilization across multiple specialties by patients whose comorbidities are partly driven by uncontrolled apnea.
Motor vehicle accident risk in untreated sleep apnea patients is estimated to be two to seven times higher than in the general population, driven by excessive daytime sleepiness impairing reaction time and sustained attention. The cost of sleep apnea-related traffic accidents alone has been estimated in the billions of dollars annually in the United States.
Studies examining the healthcare costs of undiagnosed sleep apnea patients have found that they utilize significantly more healthcare resources — across emergency visits, hospitalizations, and specialist consultations — than matched patients without sleep apnea, in the years before their eventual diagnosis. This suggests that the cost of not diagnosing sleep apnea substantially exceeds the cost of testing and treatment.
Treatment Rates and Adherence
Among the patients who are diagnosed, treatment uptake and adherence present their own statistical picture. CPAP is prescribed to the large majority of diagnosed patients, but long-term adherence — defined as consistent use meeting the clinical threshold of four hours per night on 70% of nights — is achieved by roughly half of patients in most real-world studies. This means that even among the diagnosed minority, a significant proportion are not receiving the full benefit of available treatment.
Improving adherence is one of the primary focuses of sleep medicine research and clinical practice, because the gap between prescribed therapy and effective therapy represents a substantial lost opportunity for health benefit in a population already selected for diagnosis — itself a fraction of those affected.
What the Numbers Mean in Practice
The cumulative picture painted by sleep apnea facts and statistics is one of a condition that is extraordinarily prevalent, dramatically underdiagnosed, and associated with serious and well-documented health consequences that are substantially modifiable with treatment. The numbers make a straightforward case for lower diagnostic thresholds, more systematic screening in primary care, and greater awareness among both patients and providers of what sleep apnea is and what it does when left untreated.